Anton Beffa, MD
Ophthalmology · Farmington, MONPI 1306815345
Payments from drug & device makers
Across 237 payments — averaging $20.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$932
- AbbVie$757
- Mallinckrodt Hospital Products Inc.$472
- Bausch & Lomb Americas Inc.$419
- Glaukos Corporation$346
- Tarsus Pharmaceuticals, Inc.$239
- plus $2K from 19 others
What the payments were for
- Food & beverage$4,79898%
- Education$1182%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 35 | $932 |
| AbbVie(2 entities) | 47 | $757 |
| Mallinckrodt Hospital Products Inc. | 17 | $472 |
| Bausch & Lomb Americas Inc. | 22 | $419 |
| Glaukos Corporation | 5 | $346 |
| Tarsus Pharmaceuticals, Inc. | 13 | $239 |
| Aerie Pharmaceuticals, Inc. | 12 | $236 |
| Novartis | 16 | $218 |
| Oyster Point Pharma, Inc. | 8 | $210 |
| Eyevance Pharmaceuticals LLC | 12 | $193 |
| Sun Pharmaceutical Industries Inc. | 10 | $184 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $167 |
| Thea Pharma Inc. | 5 | $99 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $86 |
| Biotissue Holdings Inc. | 9 | $57 |
| Sight Sciences, Inc. | 1 | $53 |
| Dompe US, Inc. | 2 | $53 |
| NEW World Medical,inc. | 3 | $52 |
| Harrow Eye, LLC | 2 | $45 |
| Shire North American Group Inc | 1 | $21 |
| Rayner Intraocular Lenses Limited | 1 | $20 |
| Amgen | 1 | $17 |
| Eyepoint US, Inc. | 1 | $15 |
| Kala Pharmaceuticals, Inc. | 1 | $13 |
| Ocular Therapeutix, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,916 in reported general payments places this provider in the 70th percentile of 286 ophthalmology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 79 | $77,654 |
| VyzultaLatanoprostene Bunod | 163 | $71,259 |
| XiidraLifitegrast | 56 | $57,267 |
| XdemvyLotilaner | 29 | $55,960 |
| LumiganBimatoprost | 113 | $55,626 |
| RhopressaNetarsudil Mesylate | 55 | $20,601 |
| RocklatanNetarsudil Mesylat/Latanoprost | 34 | $20,473 |
| MieboPerfluorohexyloctane/Pf | 23 | $17,008 |
| Prednisolone Acetate | 307 | $15,618 |
| Cyclosporine | 28 | $13,553 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 45 | $12,200 |
| Brimonidine Tartrate | 153 | $11,240 |
| CombiganBrimonidine Tartrate/Timolol | 31 | $9,090 |
| MoxifloxacinMoxifloxacin Hcl | 279 | $7,572 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 43 | $5,834 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $757 | $148,134234 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra, Miebo | $419 | $145,533242 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $239 | $55,96029 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $236 | $41,07489 claims |
| AlconSimbrinza | $932 | $12,20045 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 286 ophthalmology providers in Missouri.
Other ophthalmology in Farmington
- Nancy HolekampChesterfield$2.7M
- Steven SilversteinKansas City$1.6M
- Joseph TauberKansas City$1.3M
- Steven CouchSaint Louis$1.2M
- Andrew MoyesKansas City$1.1M
- Ranjan MalhotraSaint Louis$964K
- Navin TekwaniSaint Louis$957K
- Joseph GiraDes Peres$926K
- Michael KorenfeldWashington$821K
- Gregg BerdySaint Louis$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.